Novartis said it has won the regulatory approval for three-in-one combination treatment for asthma. The formulation combines the bronchodilation of indacaterol acetate (a LABA) and glycopyrronium bromide (a LAMA) with mometasone furoate (ICS).

The Ministry of Food and Drug Safety granted the license for Enerzair Inhalation Cap. (ingredient: mometasone, indacaterol, glycopyrronium), and Attactra Inhalation Cap. (mometasone, indacaterol), as a once-daily maintenance treatment of asthma.

In about 40 percent of patients with asthma, the disease has remained uncontrolled. With the latest nod, Novartis can provide more treatment options for asthma patients, the company said.

The three-in-one combo Enerzair comes in two doses – a medium dose of 80·150·50μg and a high dose of 160·150·50μg. The two-in-one combo Attactra comes in three doses – a low dose of 80·150μg, a medium dose of 160·150μg, and a high dose of 320·150μg.

Enerzair proved effective in improving patients’ quality of life when compared with a combination of Attracta and LAMA, according to the company.

Song Kyung-ryung, head of immunology, hepatology, and dermatology & respiratory at Novartis Korea, said the company could provide broader treatment options for asthma patients from stage 2 to stage 5 defined by Global Initiative for Asthma.

“We hope that our new treatments can help asthma patients, who have suffered from insufficient control of their symptoms, to lead a better life.”